Satisfying result after endpoint management laser in acute central serous chorioretinopathy: a case report
DOI:
https://doi.org/10.18203/2349-3933.ijam20243066Keywords:
EpM laser, CSCR, Acute, SurgeryAbstract
Central serous chorioretinopathy (CSC) is a condition where there is a buildup of fluid under the retina, specifically at the macula, causing neurosensory retinal detachment. This condition affected by many factors, one of them was psychological stress and male gender. CSC is a self-limiting disease, but in acute, chronic, and recurrent CSC in functionally monocular patient also could be considered as giving treatment. We presented a case of a 44 years old functionally monocular patient treated successfully with Endpoint management (EpM) Laser. After EpM laser was done, the subretinal fluid absorbed resolved, no darker spot straight ahead, and central foveal thickness in right eye was decreasing on the 14th day post operative. Treatment of CSC with visual loss is successful and efficient with EpM laser. Without harming retinal pigment epithelium, it accelerates sub-retinal fluid absorption and enhances visual rehabilitation.
Metrics
References
Fung AT, Yang Y, Kam AW. Central serous chorioretinopathy: A review. Clin Exp Ophthalmol 2023;51:24370.
Annam R, Padyala P, Annam P, Nandennagari S, Bethala K. Risks and Management of Central Serous Chorioretinopathy in a Middle-Aged Female. Cureus. 2023;15(12).
Mccannel CA, Kim SJ. 2021-2022 Basic and clinical science course, section 12: retina and vitreous. Transl Vis Sci and Technol. 2021;12(11):33.
Mrejen S, Balaratnasingam C, Kaden TR, Bottini A, Dansingani K, Bhavsar KV, et al. Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmol. 2019;126:576–88.
Nursalim AJ, Sumual V. Central serous chorioretinopathy induced by work stress: a case report. Clini C. 2020;8:246–50.
Schworm B, Siedlecki J, Keidel LF, Herold TR, Luft N, Priglinger SG. Subthreshold laser therapy with a standardized macular treatment pattern in chronic central serous chorioretinopathy. Graefe’s Arch Clin Exp Ophthalmol. 2021;259:3271–81.
Matet A, Jaworski T, Bousquet E, Canonica J, Gobeaux C, Daruich A, et al. Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy. Scientific Reports. 2020;10(1):20175.
Ong J, Selvam A, Maltsev DS, Zhang X, Wu L, Chhablani J. Subthreshold laser systems: a narrative review of the current status and advancements for retinal diseases. Annals of Eye Science. 2022;7:15.
Ong J, Selvam A, Maltsev DS, Zhang X, Wu L, Chhablani J. Subthreshold laser systems: a narrative review of the current status and advancements for retinal diseases. Annals of Eye Science. 2022;7:15.
Shekoh N-U-A, Shekoh Q, Gonzalez V. Endpoint management in central serous chorioretinopathy. Investig Ophthalmol Vis Sci. 202;62:2206.